
Jan 6 (Reuters) - Taysha Gene Therapies Inc TSHA.O:
TAYSHA GENE THERAPIES ANNOUNCES PROGRESS ACROSS TSHA-102 PIVOTAL GENE THERAPY PROGRAM IN RETT SYNDROME
TAYSHA GENE THERAPIES: COMPLETION OF DOSING IN REVEAL PIVOTAL TRIAL & ASPIRE TRIAL EXPECTED IN Q2 2026
TAYSHA GENE THERAPIES : LONGER-TERM SAFETY & EFFICACY DATA UPDATE FROM PART A OF REVEAL PHASE 1/2 TRIALS EXPECTED IN H1 2026